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Colorectal cancerThe peptide hormone gastrin has been identiﬁed as a major regulator of acid secretion and a potent mitogen
for normal andmalignant gastrointestinal cells. The importance of gastric acid in the absorption of dietary iron
ﬁrst became evident 50 years ago when iron deﬁciency anemia was recognized as a long-term consequence of
partial gastrectomy. This review summarizes the connections between circulating gastrins, iron status and
colorectal cancer. Gastrins bind two ferric ions with micromolar afﬁnity and, in the case of non-amidated
forms of the hormone, iron binding is essential for biological activity in vitro and in vivo. The demonstration of
an interaction between gastrin and transferrin by biochemical techniques led to the proposal that gastrins
catalyze the loading of transferrin with iron. Several lines of evidence, including the facts that the
concentrations of circulating gastrins are increased in mice and humans with the iron overload disease
hemochromatosis and that transferrin saturation positively correlates with circulating gastrin concentration,
suggest the potential involvement of gastrins in iron homeostasis. Conversely, recognition that ferric ions play
an unexpected role in the biological activity of gastrins may assist in the development of useful therapies for
colorectal carcinoma and other disorders of mucosal proliferation in the gastrointestinal tract.carcinoma; Dcytb, a duodenal
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The peptide hormone gastrin was ﬁrst identiﬁed as a stimulant
of gastric acid secretion [1]. The recognition that iron deﬁciency
anemia was a long-term consequence of partial gastrectomy
indicated the importance of gastric acid in the absorption of dietary
iron [2,3]. However over the past decade evidence has been
accumulating that gastrin and its precursors may be directly
involved in iron homeostasis [4–6]. Since gastrin precursors also
act as growth factors for the colorectal mucosa [7,8], this review
will explore the connections between gastrins and iron homeostasis,
and the implications of those connections for the development of
colorectal cancer.
2. Gastrins and gastrin receptors
In 1905 the British physiologist John Edkins postulated the
existence of gastrin as a hormonal regulator responsible for
stimulating gastric acid secretion [1]. Fifty years later, Gregory andTracy puriﬁed sufﬁcient gastrin to determine its amino acid
sequence [9,10]. Cloning of gastrin mRNA subsequently revealed
that all forms of gastrin are generated from an 80 amino acid
precursor, progastrin [11], which is cleaved at dibasic sequences by
prohormone convertases [12,13] (Fig. 1). Subsequent removal of
Arg73 and Arg74 by carboxypeptidase E yields glycine-extended
gastrin34 and glycine-extended gastrin17 (Ggly), and oxidative
cleavage by peptidylglycine α-amidating monooxygenase results
in C-terminally amidated gastrin17 (Gamide) [12]. Many of the
physiological effects of Gamide are mediated by the cholecystoki-
nin2 (CCK2) receptor [14], which recognizes the amidated C-
terminal tetrapeptide of gastrin [15]. Gamide was recently shown to
increase expression of the gastrin gene via a CCK2 receptor-
dependent autocrine loop [16].
Non-amidated gastrins like progastrin and Ggly elicit biological
effects in different tissues from Gamide (Fig. 2). The latter targets the
gastric mucosa, whereas non-amidated gastrins are principally active in
the colon. Transgenic mice which overexpress progastrin (hGAS) [17]
showed a two-fold increase in basal proliferation rate in the colonic
mucosa, while gastrin-deﬁcient (Gas−/−) mice showed decreased
colonic proliferation [18]. Trophic effects of Ggly were demonstrated
in mice overexpressing progastrin truncated at Gly72 (MTI/Ggly), with
increased colonicmucosal thickness, an increasednumberof goblet cells
per crypt and increased colonic proliferation compared with wild-type
controls [19]. When circulating Ggly concentrations were increased in
Gas−/−mice by continuous infusion for two weeks, increases in colonic
mucosal thickness and proliferationwere observed compared to saline-
Fig. 1. Gastrin processing. Preprogastrin (101 amino acids) is converted to progastrin (80 amino acids) by removal of its signal peptide (black box). The sequential action of
prohormone convertases and carboxypeptidase E then converts the prohormone to glycine-extended forms such as glycine-extended gastrin34 (progastrin38–72) and glycine-
extended gastrin17 (progastrin55–72, Ggly). The extent of transamidation of glycine-extended gastrin34 to amidated gastrin34 by peptidyl α-amidating monooxygenase is dependent
on the tissue. Finally amidated gastrin34 is cleaved to amidated gastrin17 (Gamide) by prohormone convertases. The sequence of Gamide is ZGPWLEEEEEAYGWMDFamide, where Z
represents a pyroglutamate residue. Both non-amidated and amidated forms of gastrin are independently active via different receptors. The CCK2 receptor recognizes the amidated
C-terminal tetrapeptide of gastrin [15], while the Ggly receptor recognizes the ferric ion complexes of the central heptapeptides LEEEEEA and EEEEEAY [77].
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colostomy to create a defunctioned rectum caused an increase in the
proliferation of the rectal mucosa [20]. Infusion of Ggly into rats also
increased numbers of aberrant crypt foci in the colorectal mucosa after
treatment with the carcinogen azoxymethane [20].
The identities of the receptors for non-amidated gastrins are still
the subject of controversy (see [7] for a summary of early work in this
area). Possible candidates include the 78 kDa gastrin-binding protein
[21] and annexin II [22]. Progastrin [23,24] and Ggly [25] do not bind
to the CCK2 receptor, butmore detailed binding studies of the afﬁnitesFig. 2. Physiological actions of progastrin-derived peptides. Gamide is now recognized
as the primary stimulant of gastric acid secretion. Gamide is released from the gastric
antral mucosa into the circulation, binds to CCK2 receptors (CCK2R) on ECL cells in the
gastric fundic mucosa, and stimulates histamine release. Histamine together with
gastrin then stimulates the release of acid from fundic parietal cells. Ggly alone is unable
to stimulate acid secretion but potentiates acid release in response to Gamide. The
abundant evidence that Gamide acts as a growth factor in the gastric mucosa has been
reviewed previously [7]. Gamide was recently shown to increase expression of the
gastrin gene via a CCK2 receptor-dependent (CCK2R dept) autocrine loop [16]. In
contrast the trophic effects of non-amidated gastrins like progastrin and Ggly are
principally seen in the colon. In mice overexpression of progastrin or Ggly increases the
basal proliferation rate in the colonic mucosa [18]. In rats, short-term administration of
Ggly after colostomy to create a defunctioned rectum caused an increase in the
proliferation of the rectal mucosa [20]. The stimulation of proliferation in bothmodels is
blocked by the chelating agent desferrioxamine, presumably by removal of ferric ions
[78]. Progastrin [23,24] and Ggly [25] do not bind to the CCK2 receptor, but the
stimulatory effects of progastrin on proliferation in mouse colonic mucosa are not
observed in Cck2r−/− mice [91].of progastrin, Ggly and Gamide for all candidate receptors for non-
amidated gastrins are urgently required.
3. Role of gastrins in acid secretion
Gamide is now recognized as the primary secretagogue for meal-
stimulated acid secretion [12]. G cells in the gastric antrum are the
predominant site of synthesis of progastrin and storage ofGamidewhich,
upon luminal stimulation by amino acids or peptides, is released into the
circulation and transported to the fundic mucosa where it binds to CCK2
receptorsonECL cells. Theacid secretoryactionofGamide ismediatedvia
the release of histamine fromECL cells and the subsequent stimulation of
parietal cells by histamine to produce H+ [26]. Gamide also directly
stimulates theparietal cell [27], andCCK2 receptor antagonists havebeen
used to conﬁrm the involvement of Gamide in gastric acid secretion [28].
In contrast, Ggly alone does not stimulate acid secretion, but potentiates
the stimulation observed in response to Gamide [29,30].
Studies ofmice geneticallymodiﬁedbydisruption of theGas orCck2r
genes have clariﬁed the role of gastrin inacid secretion. Basal gastric acid
secretion was abolished in Gas−/− mice and could not be induced by
subcutaneous injection of histamine, carbachol, or Gamide, probably
because of defective parietal cell maturation [18,31]. In contrast,
continuous perfusion of Gas−/− mice with Gamide partially restored
acid secretion [31]. The Cck2r−/− mice on the other hand had an
approximately 10-fold increase in plasma Gamide concentration
comparedwithwild-type controls but had reduced numbers of parietal
and ECL cells and an increased basal gastric pH (from 3.2 to 5.2) [32,33].
Hence the absence of the CCK2 receptor presumably results in defective
ECL and parietal cell maturation, reduced histamine secretion by ECL
cells, and reduced acid secretion by parietal cells [32,33].
4. Acid secretion and anemia
The bioavailability of non-heme iron is increased by gastric acidity
by two mechanisms [34,35]. Firstly, the high concentration of
hydrogen ions at acidic pH (pH 3=1 mM H+) leads to efﬁcient
competition for metal ion binding sites in dietary components, and so
liberates more iron from food. Secondly, the released ferric ions are
only soluble in aqueous solutions at acidic pH. Hence the low pH of the
stomach lumen caused by secretion of acid keeps iron soluble and
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absorption in the small intestine [36–38]. In contrast, gastric acid is
not required for the absorption of heme iron [34].
The importance of gastric acid for iron absorption became evident
about 50 years ago, when Baird and others reported that iron deﬁciency
anemia is a long-term consequence of partial gastrectomy [2,3,39–42].
Subsequent radioiron studies demonstrated decreased absorption of
dietary non-heme iron in patients with achlorhydria [43–45], or after
treatment with the histamine H2 receptor antagonist cimetidine [46].
The proton pump inhibitor omeprazole caused profound hypochlorhy-
dria by inhibiting acid secretion, and treatmentwith omeprazole in rats
on an iron-deﬁcient diet caused anemia [47]. For a number of years
investigators failed to demonstrate any association between omepra-
zole treatment and anemia in non-anemic, iron-replete individuals
[38,48]. However, a recent study in patients with established iron
deﬁciency showed that omeprazole did in fact contribute to iron
deﬁciency anemia via impairment of the absorption of orally adminis-
tered iron [49]. In contrast, hypergastrinemic patients with Zollinger–
Ellison syndrome did not develop iron deﬁciency anemia after
omeprazole treatment [38].
5. Iron uptake by the intestinal epithelium
Because of the absence of excretory mechanisms, the intestinal
absorption of dietary iron is a critical regulatory point of iron
homeostasis (Fig. 3). Although at physiological pH in the presence of
oxygen iron exists in the insoluble ferric form (Fe3+), most iron
transport systems take up iron in the soluble ferrous form (Fe2+). Ferric
iron from food is therefore ﬁrst reduced to ferrous iron by ferric
reductases associated with the enterocyte apical membrane. An
attractive candidate reductase is Dcytb, a cytochrome b-like ferric
reductase of the duodenal mucosa, expression of which increases in
response to iron deﬁciency andhypoxia [50]. However, other reductases
may also be present in the brush border as Dcytb−/− mice do not
develop iron deﬁciency [51]. The reduced iron is then transported into
epithelial cells by divalent metal ion transporter 1 (DMT-1) [52]. The
expression of DMT-1 on the apical membrane of the enterocyte is
regulated by body iron status such that its level is increased in iron
deﬁciency and decreased in iron overload [52]. The observation that
targeted disruption of the mouse Dmt-1 gene leads to a profound
microcytic, hypochromic anemia suggests that this transporter plays an
important role in intestinal iron absorption and in erythropoiesis [51].
6. Iron export from the enterocyte
Ferrous iron in the enterocyte passes to the basolateral membrane
for export into the circulation via the iron transporter ferroportin [53].
Targeted disruption of the mouse ferroportin gene demonstrated the
importance of ferroportin both in intestinal iron absorption and in iron
release from tissues, as Fpn−/− animals were anemic and retained
excess iron in enterocytes, macrophages and hepatocytes [54]. In
addition to ferroportin, the ferrous oxidases hephaestin and ceruloplas-
min are required for iron release from enterocytes [55,56]. Hephaestin,
which is associated with the basolateral side of the enterocyte where it
oxidizes Fe2+ to Fe3+, appears to be the major ferrous oxidase in the
intestine under normal conditions [55]. Circulating ceruloplasmin can
also play a role in iron absorption when iron demands are particularly
high [57].
Release of iron from duodenal enterocytes into the plasma is
controlled by hepcidin. Hepcidin was ﬁrst identiﬁed as a 25 amino acid
anti-microbial peptide in urine [58], but is now recognized as a major
regulator of iron homeostasis [59,60]. Hepcidin is produced primarily by
the liver [61], and its expression and circulating concentration are
increased in cases of increased serum iron, iron overload [60] and
inﬂammation [62], and decreased in response to higher erythropoietic
demand, hypoxia and iron deﬁciency [62]. In addition, humans withmutations in the hepcidin gene develop severe iron overload [63]. The
iron exporter ferroportin is the receptor for hepcidin and, as a
consequence of binding, ferroportin is internalized and degraded,
leading to decreased export of cellular iron [64,65]. Thus increased
hepcidin leads to reduced ferroportin expression in enterocytes,
decreased intestinal iron absorption and reduced availability of iron to
cells of the body. Conversely, under hypoxic conditions, coordinate
downregulation of hepcidin (with a consequent increase in ferroportin)
and upregulation of erythropoietin results in increased iron for
biological functions including erythrocyte production [66].
7. Transferrin saturation and the sensing of body iron stores
Serum transferrin plays a key role in iron metabolism by accepting
newly absorbed iron from the gut and stored iron from the tissues and
transporting iron to cells expressing transferrin receptors. Transferrin
receptor 1 (TfR1) is the major receptor for cellular iron uptake (via the
endocyticpathway) and is expressedonalmost all cells,withmature red
blood cells being one of the very few exceptions [67]. Transferrin
receptor 2 (TfR2) on the other hand is foundmainly on hepatocytes and
is upregulated in response to increased transferrin saturation [68,69].
Although both receptors bind iron-loaded transferrin with high afﬁnity,
the afﬁnity of TfR2 for transferrin is considerably lower than that of TfR1
[70]. The observation thatmutations in TfR2 cause a rare formof the iron
overloaddisease hereditary hemochromatosis suggests that this protein
plays amore important role in the regulationof ironhomeostasis than in
cellular iron uptake [71].
It is now generally agreed that diferric transferrin acts as a sensor for
body iron requirements and is an important signal to alter hepcidin
expression [72]. How transferrin achieves this is incompletely under-
stood, but twomodels have beenproposed [73,74]. Bothmodels suggest
that in basal and low iron states, TfR1 forms a complex with HFE (the
protein commonly mutated in hemochromatosis) and that diferric Tf
competes with HFE for binding of TfR1. In the Frazer/Anderson model
[73], the displaced HFE on the surface of hepatocytes stimulates a
signalling cascade that results in increased production of hepcidin, and
the plentiful supply of diferric transferrin also allows it to bind to TfR2
further stimulating hepcidin expression. In the Goswami/Andrews
model [74], dissociation of the HFE/TfR1 complex by diferric transferrin
allows HFE to bind to TfR2, with subsequent stimulation of hepcidin
expression. Thus the twomodels differ inwhether hecidin production is
increased by HFE acting alone [73] or as a complex with TfR2 [74]. Since
mice lackingbothHfe and Tfr2 have amore severe phenotype thanmice
lacking either gene alone [75], at least some of the effects of Hfe and Tfr2
on hepcidin expression are probably independent. Irrespective of the
mechanism, in each of these models transferrin saturation controls
expression of the iron homeostasis regulator hepcidin.
8. Gastrins and iron: Structural studies
Both Ggly and Gamide bind two ferric ions in aqueous solution [4].
Fluorescence quenching experiments with peptides derived from the
Ggly sequence indicated that one or more of the ﬁve glutamic acid
residues were necessary for iron binding [4]. The solution structure of
Ggly was determined by nuclear magnetic resonance (NMR)
spectroscopy and the identity of the iron binding ligands by NMR
spectroscopy and by mutation. Glutamate7 was a ligand at the ﬁrst
ferric iron binding site, and glutamate8 and glutamate9 were ligands
at the second ferric iron binding site [76]. The role of ferric ion binding
in the stimulation of proliferation and migration by Ggly was then
investigated in the mouse gastric cell line IMGE-5. The observations
that the iron chelator desferrioxamine inhibited the biological action
of Ggly, and that the GglyE7A mutant, which has impaired iron
binding, was biologically inactive, suggested that binding of ferric ions
to Ggly was essential for the peptide's biological activity [76]. Further
studies of gastrin fragments revealed that the heptapeptides LE5A and
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essential for proliferative activity [77]. Ferric ions are also essential
for the biological effects of Ggly and progastrin in vivo, since
desferrioxamine blocked the stimulation of proliferation by non-
amidated gastrins in rat and mouse colonic mucosa [78]. The simplest
conclusion consistent with all of the above data is that the Ggly
receptor recognizes only the ferric ion complex of Ggly. In contrast,
the observations that desferrioxamine had no effect on the binding of
Gamide to the CCK2 receptor, or on the biological activity of Gamide,
clearly indicate that ferric ions were not essential in this case and
hence conﬁrm that the CCK2 receptor and the Ggly receptor are
different [79]. The latter conclusion is consistent with the early
observation that the minimum requirement for binding to the CCK2
receptor is the amidated C-terminal tetrapeptide of gastrin [15].
Both Gamide and Ggly have also been shown to interact with the
iron transport protein transferrin. The interaction of Gamide with
transferrin was ﬁrst detected in extracts of porcine gastric mucosa
using covalent cross-linking assays, which demonstrated that the
concentration of Gamide required to reduce cross-linking by 50% was
approximately 100 μM [80]. A more detailed ultracentrifugal study
subsequently revealed that apo-transferrin (iron-free transferrin)
bound two molecules of Gamide with a Kd of 6.4 μM at pH 7.4 [81]. No
signiﬁcant binding of Gamide to diferric transferrin was detected
under the same conditions. Interaction between apo-transferrin and
Ggly was later detected by surface plasmon resonance [82]. The fact
that no interaction between apo-transferrin and either Gamide or
Ggly was observed in the presence of the chelator EDTA suggested
that the gastrin–ferric ion complex was the interacting species [82].
9. Gastrins and iron: Biological connections
In addition to the strong evidence that a gastrin–ferric ion complex
forms in solution and interacts with apo-transferrin, accumulating data
support the existence of a more general connection between iron status
and gastrins. Gamide and Ggly concentrations were increased in the
gastric mucosa and plasma of Hfe−/− mice, and in the sera of patients
with HFE-related hemochromatosis [5]. The observed changes in gastrin
inHfe−/−mice were not due to structural changes in the gastric mucosa,
which contained normal numbers of parietal cells, or to reduced gastric
acid production, as the pH of the luminal contents was lower in Hfe−/−
mice than in wild-type animals. Precisely how HFE deﬁciency and
gastrins are linked remains unresolved. Conversely, modulation of
circulating gastrin concentrations was also shown to alter iron
homeostasis. The concentration of hepcidin mRNA in the gastric mucosa
ofGas−/−micewas only 40% of the value inwild-typemice, but returned
to 130% of thewild-type value after subcutaneous infusion of Gamide for
1 week [83]. In juvenileGas−/−mice, intestinal iron absorptionmeasured
by 59Fe uptake after oral gavage was increased sixfold, and concentra-
tions of Dmt-1 mRNA were increased fourfold, compared with age-
matched wild-type mice [6]. The increased absorption probably reﬂects
systemic iron deﬁciency in these animals and the reduction in hepatic
hepcidin expression supports this proposal [6]. Although there was no
signiﬁcant change in iron absorption in hypergastrinemic Cck2r−/−mice,
Dmt-1 mRNA was 5.4-fold higher than in age-matched wild-type mice.
Importantly, transferrin saturation was reduced by 20% in Gas−/−mice,
and increased by 50% in Cck2r−/−mice, compared to age-matchedwild-
type mice. Similarly, in humans hypergastrinemic because of multiple
endocrine neoplasia type I, transferrin saturation correlated positively
with circulating Gamide concentrations [6].
A mechanism has been proposed [6] for the connection between
changes in circulating Gamide concentrations and changes in
transferrin saturation (Fig. 3). The model proposes that, after export
of ferrous ions from the enterocyte by ferroportin and their oxidation
to ferric ions by hephaestin, circulating Gamide or Ggly may act as
chaperones for the uptake of ferric ions by apo-transferrin. The failure
to detect signiﬁcant binding of Gamide or Ggly to diferric transferrin[81] suggests that both Gamide and Ggly dissociate after iron transfer
has occurred and hence play a catalytic role consistent with the
difference in the circulating concentrations of transferrin and Gamide
or Ggly. Changes in the circulating concentration of diferric transferrin
may in turn cause signiﬁcant alterations in iron trafﬁc into and
throughout the body by altering the production of the regulatory
peptide hepcidin by the liver [73]. Themodel predicts that increases in
circulating gastrins would lead to an increase in iron stores, as was
observed in hypergastrinaemic Cck2r−/− mice [6].
10. Relevance to colorectal cancer
There is now abundant evidence that non-amidated gastrins
accelerate the development of colorectal carcinoma (CRC) [7,84].
Colorectal cancers express progastrin in greater amounts than normal
colorectal mucosa [85], and patients with colorectal adenocarcinoma
have increased circulating concentrations of Gamide and total gastrins
[86]. A retrospective study by Thorburn and co-workers provided
additional evidence that increased circulating Gamide concentrations
contribute to the increased risk of colon cancer [87].
Both progastrin and Ggly are also active in mouse models of colon
cancer. In theMin+/−mouse model of intestinal polyposis, infusion of
Ggly increased the number of polyps [88] and increased numbers of
polyps were also observedwhenMin+/−mice were crossedwithMTI/
Ggly mice which overexpressed Ggly [19]. Transgenic mice that
overexpress progastrin developed more aberrant crypt foci [89] and
colon cancers [90] in response to the mutagen azoxymethane than
wild-type mice. The observation that the stimulatory effects of
progastrin on CRC development are not apparent in Cck2r−/− mice
is rather surprising [91], since progastrin does not bind to the CCK2
receptor [23,24]. In vitro, Ggly stimulated proliferation and migration
of the mouse colon cell line YAMC [92] and invasion and migration of
the human CRC cell line LoVo [93]. In other cell lines Ggly also
stimulated proliferation [94] and the stimulation could be blocked
with gastrin antisense constructs [95] or by immunization with a
gastrin–diphtheria toxin conjugate (gastrimmune) [96].
The importance of iron in colorectal carcinogenesis is becoming
increasingly recognized [97]. Dietary iron has been identiﬁed as a risk
factor for CRC [98,99], and mutations in the HFE gene in hemochro-
matotic patients are associated with increased risk of CRC [100,101].
Examination of resected polyps and CRC showed that progression to
CRC was associated with increased expression of iron import proteins
and decreased expression of iron export proteins [102]. The resultant
increase in intracellular ironmay act to stimulate growth of the tumor
cells and may also initiate/promote carcinogenesis through produc-
tion of reactive oxygen species and DNA damage. Alternatively, since
progastrin and Ggly act as colonic growth factors, the increased
circulating Ggly concentrations in the plasma of hemochromatotic
patients and Hfe−/− mice may contribute to the development of CRC
[5]. Although the precise mechanisms underlying the involvement of
gastrins in iron homeostasis are still unknown, non-amidated gastrins
and iron may contribute synergistically to the development of CRC
(Fig. 3).
11. Future perspectives
The recognition that ferric ions are essential for the biological
activities of non-amidated gastrins suggests several new possibilities
for the treatment of CRC. Removal of ferric ions with chelating agents
blocked Ggly activity in vitro [76] and in vivo [78]. Occupation of the
Ggly metal ion binding site by bismuth ions prevented the binding of
ferric ions, and so rendered the peptide inactive [79]. The major
advantage of both approaches is the speciﬁcity of inactivation, since
neither has any effect on the activity of amidated gastrins [103]. On
the other hand a degree of caution would be required if treating CRC
patients with chelating agents as many also present with iron
Fig. 3. A possible dual role for gastrin in iron homeostasis and colorectal cancer. The ﬁrst role of gastrins in the stomach is well established. Following a meal, Gamide is released from
the gastric antral mucosa into the circulation and stimulates the release of histamine from ECL cells in the gastric fundic mucosa. Histamine together with gastrin then stimulates
fundic parietal cells to release acid into the gastric lumen. Ggly alone is unable to stimulate acid secretion but potentiates acid release in response to Gamide. Presumably the
potentiation of acid release will, like the other biological activities of Ggly, be dependent on ferric (Fe3+) ions. The acid released will compete for iron binding sites present in dietary
components, and hence increase the concentration of soluble Fe3+ ions passing into the duodenum. The cytochrome b-like ferric reductase Dcytb, present on the villi of duodenal
enterocytes, reduces Fe3+ to ferrous (Fe2+) ions, which are then transported into the enterocyte by the divalent metal ion transporter DMT-1. Fe2+ ions are exported into the
circulation by ferroportin, and the iron regulator hepcidin controls iron export by formation of a complex with ferroportin. Internalization and degradation of the complex reduces
the amount of ferroportin on the cell surface, and hence reduces iron export. The exported Fe2+ ions are then re-oxidized to Fe3+ ions by hephaestin. The second postulated role of
gastrins increases the availability of iron in the circulation. Circulating Ggly and Gamide will bind Fe3+ ions, and the resultant complex will catalyze the loading of apo-transferrin
with iron, and hence increase the tissue availability of iron. A like process may also occur within CRC, where the non-amidated gastrins produced by the tumor will similarly catalyze
the loading of apo-transferrin (ApoTf) with iron for subsequent uptake by CRC cells. The stimulation of tumor growth by non-amidated gastrins will result from a combination of the
enhanced availability of Fe-transferrin (FeTf) and of direct effects on the tumor cells, with the relative importance of the two components as yet undeﬁned.
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secretion by amidated gastrins [29,30], such inhibitors may also be
useful for the treatment of excessive acid production in patients with
gastrointestinal ulcers.
In addition, the demonstration that plasma gastrin concentrations
were increased in mice with defects in iron homeostasis [5] opens a
completely new perspective for understanding the control of iron
metabolism in vivo. Further investigation of the mechanisms involved
may lead to novel therapies for aberrant iron homeostasis in humans. In
this context it is worth remembering that iron overload is not an
uncommon disease. A recent population study from Australia reported
that 0.65% of the study group were homozygous for the HFE mutation
C282Y, and of these homozygotes documented iron overload-related
disease developed in 28% of men and 1.2% of women [105]. The
signiﬁcance of this observation is that liver ﬁbrosis, cirrhosis and
hepatocellular carcinoma were common sequelae of iron overload
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